首页> 美国卫生研究院文献>other >Oxytocin in Uniject Disposable Auto-Disable Injection System versus Standard Use for the Prevention of Postpartum Hemorrhage in Latin America and the Caribbean: A Cost-Effectiveness Analysis
【2h】

Oxytocin in Uniject Disposable Auto-Disable Injection System versus Standard Use for the Prevention of Postpartum Hemorrhage in Latin America and the Caribbean: A Cost-Effectiveness Analysis

机译:Uniject一次性自动禁用注射系统中的催产素与标准用法在拉丁美洲和加勒比海地区预防产后出血的成本效果分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Postpartum hemorrhage (PPH) is a leading cause of maternal death. Despite strong evidence showing the efficacy of routine oxytocin in preventing PPH, the proportion of women receiving it after delivery is still below 100%. The Uniject injection system prefilled with oxytocin (Uniject) has the potential advantage, due to its ease of use, to increase oxytocin utilization rates. We aimed to assess its cost-effectiveness in Latin America and the Caribbean (LAC). We used an epidemiological model to estimate: a) the impact of replacing oxytocin in ampoules with Uniject on the incidence of PPH, quality-adjusted life years (QALYs) and costs from a health care system perspective, and b) the minimum increment in oxytocin utilization rates required to make Uniject a cost-effective strategy. A consensus panel of LAC experts was convened to quantify the expected increase in oxytocin rates as a consequence of making Uniject available. Deterministic and probabilistic sensitivity analyses were performed. In the base case, the incremental cost of Uniject with respect to oxytocin in ampoules was estimated to be USD 1.00 (2013 US dollars). In the cost-effectiveness analysis, Uniject ranged from being cost-saving (in 8 out of 30 countries) to having an incremental cost-effectiveness ratio (ICER) of USD 8,990 per QALY gained. In most countries these ICERs were below one GDP per capita. The minimum required increment in oxytocin rates to make Uniject a cost-effective strategy ranged from 1.3% in Suriname to 16.2% in Haiti. Switching to Uniject could prevent more than 40,000 PPH events annually in LAC. Uniject was cost-saving or very cost-effective in almost all countries. Even if countries can achieve only small increases in oxytocin rates by incorporating Uniject, this strategy could be considered a highly efficient use of resources. These results were robust in the sensitivity analysis under a wide range of assumptions.
机译:产后出血(PPH)是孕产妇死亡的主要原因。尽管有强有力的证据表明常规催产素能预防PPH,但分娩后接受催产素的妇女比例仍低于100%。预装了催产素的Uniject注射系统(Uniject)由于易于使用,具有提高催产素利用率的潜在优势。我们旨在评估其在拉丁美洲和加勒比海(LAC)的成本效益。我们使用一种流行病学模型来估计:a)从卫生保健系统的角度,用Uniject替代安瓿中的催产素对PPH的发生率,质量调整生命年(QALYs)和成本的影响,以及b)催产素的最小增量使Uniject成为具有成本效益的策略所需的利用率。召集了LAC专家共识小组,以量化因提供Uniject而导致的催产素速率的预期增加。进行了确定性和概率敏感性分析。在基本情况下,Uniject相对于安瓿中催产素的增量成本估计为1.00美元(2013年美元)。在成本效益分析中,Uniject的范围从节省成本(30个国家中的8个国家)到每个QALY获得的增量成本效益比(ICER)为8,990美元。在大多数国家,这些ICERs低于人均GDP。为了使Uniject成为具有成本效益的策略,催产素率的最低要求增加范围从苏里南的1.3%到海地的16.2%。切换到Uniject可以每年在LAC阻止40,000多个PPH事件。 Uniject在几乎所有国家都节省了成本或具有很高的成本效益。即使各国通过合并Uniject只能使催产素的使用率仅小幅提高,但该策略也可以被视为资源的高效利用。在各种假设下,这些结果在敏感性分析中都非常可靠。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号